Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan

Liver Cancer

Volumn 5, Issue 3, 2016, Pages 190-197

  Kudo, Masatoshi ^a   Izumi, Namiki ^b   Sakamoto, Michiie ^c   Matsuyama, Yutaka ^d   Ichida, Takafumi ^e   Nakashima, Osamu ^f   Matsui, Osamu ^g   Ku, Yonson ^h   Kokudo, Norihiro ⁱ   Makuuchi, Masatoshi ^j  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e Shizuoka Hospital   (Japan)

^f KURUME UNIVERSITY HOSPITAL   (Japan)

^g KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^h KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j JAPANESE RED CROSS MEDICAL CENTER   (Japan)

more..

Author keywords

Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Liver Cancer Study Group of Japan; Nationwide survey; Overall survival

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER SURGERY; CHEMOEMBOLIZATION; COHORT ANALYSIS; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HUMAN; JAPAN; LIVER CELL CARCINOMA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDIAN SURVIVAL TIME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR ABLATION; TUMOR VOLUME;

EID: 85012839050     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000367775     Document Type: Article

References (27)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010;25:657-663.
3. Song P, Tang W, Tamura S, Hasegawa K, Sugawara Y, Dong J, Kokudo N: The management of hepatocellular carcinoma in Asia: a guideline combining quantitative and qualitative evaluation. Biosci Trends 2010;4:283-287.
4. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K: Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009;44(Suppl 19):102-107.
5. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:1396-1405.
6. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
7. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M: Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007;37:676-691.
8. Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, et al: Report of the 18th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2010;40:1043-1059.
9. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Liver Cancer Study Group of Japan: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469.
10. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, Ikai I: Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 2008;49:589-594.
11. Fujita T: Hepatectomy versus radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2009;50:1051-1052, author reply 1052-1053.
12. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, Makuuchi M, Liver Cancer Study Group of Japan: Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010;194:830-837.
13. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M, Liver Cancer Study Group of Japan: Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011;98:552-557.
14. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
16. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
17. Kudo M, Ueshima K, Kubo S, Sakamoto M, Tanaka M, Ikai I, Furuse J, Murakami T, Kadoya M, Kokudo N Liver Cancer Study Group of Japan (Committee for Response Evaluation Criteria in Cancer of the Liver, Liver Cancer Study Group of Japan): Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2016 Revised Version). Hepatol Res 2016;46:3-9.
18. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
19. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, Saida Y, Takayama T, Yamaoka Y: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37-51.
20. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M, HCC Expert Panel of Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-364.
21. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE: Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012;55:476-482.
22. Ries. LAG, Melbert D, Krapcho M, et al (eds.). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975-2005/,2008. Accessed February 27, 2012.
23. American Cancer Society. Cancer facts and figures 2012.
24. Park JW, Korean Liver Cancer Study Group and National Cancer Center: [Practice guideline for diagnosis and treatment of hepatocellular carcinoma]. Korean J Hepatol 2004;10:88-98.
25. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
26. El-Serag HB, Davila JA: Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol 2011;4:5-10.
27. Higashi T, Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, Sobue T, Liver Cancer Study Group of Japan: Demonstration of quality of care measurement using the Japanese liver cancer registry. Hepatol Res 2011;41:1208-1215.